keyword
MENU ▼
Read by QxMD icon Read
search

chemotherapy-induced peripheral neuropathy, CIPN

keyword
https://www.readbyqxmd.com/read/28912674/a-mechanistic-understanding-of-axon-degeneration-in-chemotherapy-induced-peripheral-neuropathy
#1
REVIEW
Yusuke Fukuda, Yihang Li, Rosalind A Segal
Chemotherapeutic agents cause many short and long term toxic side effects to peripheral nervous system (PNS) that drastically alter quality of life. Chemotherapy-induced peripheral neuropathy (CIPN) is a common and enduring disorder caused by several anti-neoplastic agents. CIPN typically presents with neuropathic pain, numbness of distal extremities, and/or oversensitivity to thermal or mechanical stimuli. This adverse side effect often requires a reduction in chemotherapy dosage or even discontinuation of treatment...
2017: Frontiers in Neuroscience
https://www.readbyqxmd.com/read/28868935/risk-reduction-and-treatment-of-chemotherapy-induced-peripheral-neuropathy
#2
Marios Bakogeorgos, Vassilis Georgoulias
Chemotherapy-induced peripheral neuropathy (CIPN), a common adverse effect of several chemotherapeutic agents, has a significant impact on quality of life and may even compromise treatment efficacy, requiring chemotherapy dose reduction or discontinuation. CIPN is predominantly related with sensory rather than motor symptoms and the most common related cytotoxic agents are platinum compounds, taxanes and vinca alkaloids. CIPN symptoms may resolve after treatment cessation, but they can also be permanent and continue for years...
September 3, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28865678/gabapentin-and-its-salicylaldehyde-derivative-alleviate-allodynia-and-hypoalgesia-in-a-cisplatin-induced-neuropathic-pain-model
#3
Nisar Ahmad, Fazal Subhan, NazarUl Islam, Muhammad Shahid, Faiz Ur Rahman, Robert D E Sewell
Cisplatin is an effective chemotherapeutic agent indicated in cancer chemotherapy. However, its clinical use is associated with peripheral neuropathy that invariably impairs patient quality of life. Gabapentin (GBP) is an effective analgesic for neuropathic pain conditions but its clinical efficacy in cisplatin-induced neuropathic pain (CINP) is limited, in addition to generating unwanted side-effects. In this study, a gabapentin-salicylaldehyde derivative [gabapentsal (GPS)] was synthesized and evaluated to explore any potential benefit in comparison with GBP in a rat model of CIPN...
August 30, 2017: European Journal of Pharmacology
https://www.readbyqxmd.com/read/28843493/utilization-of-ipsc-derived-human-neurons-for-high-throughput-drug-induced-peripheral-neuropathy-screening
#4
Payal Rana, Gregory Luerman, Dietmar Hess, Elizabeth Rubitski, Karissa Adkins, Christopher Somps
As the number of cancer survivors continues to grow, awareness of long-term toxicities and impact on quality of life after chemotherapy treatment in cancer survivors has intensified. Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most common side effects of modern chemotherapy. Animal models are used to study peripheral neuropathy and predict human risk; however, such models are labor-intensive and limited translatability between species has become a major challenge. Moreover, the mechanisms underlying CIPN have not been precisely determined and few human neuronal models to study CIPN exist...
August 24, 2017: Toxicology in Vitro: An International Journal Published in Association with BIBRA
https://www.readbyqxmd.com/read/28827818/depletion-of-nerve-growth-factor-in-chemotherapy-induced-peripheral-neuropathy-associated-with-hematologic-malignancies
#5
Jeonghwan Youk, Young-Sook Kim, Jung-Ah Lim, Dong-Yeop Shin, Youngil Koh, Soon-Tae Lee, Inho Kim
OBJECTIVE: To investigate whether the depletion of nerve growth factor (NGF) is associated with the development of chemotherapy-induced peripheral neuropathy (CIPN) in patients with hematologic malignancy. METHODS: We prospectively enrolled hematologic cancer patients who had a plan to receive bortezomib, thalidomide, or vincristine. Baseline NGF levels were measured within one week before the start date of chemotherapy. Follow-up NGF levels were measured after four months from the start date of chemotherapy or the date when CIPN was initially diagnosed...
2017: PloS One
https://www.readbyqxmd.com/read/28820525/the-content-validity-of-a-chemotherapy-induced-peripheral-neuropathy-patient-reported-outcome-measure
#6
Ellen M Lavoie Smith, Rylie Haupt, James P Kelly, Deborah Lee, Grace Kanzawa-Lee, Robert Knoerl, Celia Bridges, Paola Alberti, Nusara Prasertsri, Clare Donohoe
PURPOSE/OBJECTIVES: To test the content validity of a 16-item version of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy (QLQ-CIPN20). 
. RESEARCH APPROACH: Cross-sectional, prospective, qualitative design. 
. SETTING: Six outpatient oncology clinics within the University of Michigan Health System's comprehensive cancer center in Ann Arbor. 
...
September 1, 2017: Oncology Nursing Forum
https://www.readbyqxmd.com/read/28815646/a-novel-endpoint-for-the-assessment-of-chemotherapy-induced-peripheral-neuropathy-in-rodents-biomechanical-properties-of-peripheral-nerve
#7
Chang-Ning Liu, Edwin Berryman, David Zakur, Ahmed M Shoieb, Ingrid D Pardo, Magalie Boucher, Chris J Somps, Chedo M Bagi, Jon C Cook
Chemotherapy-induced peripheral neuropathy (CiPN) is a frequent adverse effect in patients and a leading safety consideration in oncology drug development. Although behavioral assessment and microscopic examination of the nerves and dorsal root ganglia can be incorporated into toxicity studies to assess CiPN risk, more sensitive and less labor-intensive endpoints are often lacking. In this study, rats and mice administered vincristine (75 μg kg(-1)  day(-1) , i.p., for 10 days in rats and 100 μg kg(-1)  day(-1) , i...
August 16, 2017: Journal of Applied Toxicology: JAT
https://www.readbyqxmd.com/read/28797868/neuropathic-pain-and-nerve-growth-factor-in-chemotherapy-induced-peripheral-neuropathy-prospective-clinical-pathological-study
#8
R Velasco, X Navarro, M Gil-Gil, M Herrando-Grabulosa, A Calls, J Bruna
CONTEXT: Neuropathic pain can be present in patients developing chemotherapy-induced peripheral neuropathy (CIPN). Nerve growth factor (NGF) is trophic to small sensory fibers and regulates nociception. OBJECTIVES: We investigated the changes in serum NGF and intraepidermal nerve fiber density (IENFD) in skin biopsies of cancer patients receiving neurotoxic chemotherapy in a single-center prospective observational study. METHODS: Patients were evaluated before and after chemotherapy administration...
August 7, 2017: Journal of Pain and Symptom Management
https://www.readbyqxmd.com/read/28770097/objective-evaluation-of-chemotherapy-induced-peripheral-neuropathy-using-quantitative-pain-measurement-system-pain-vision-%C3%A2-a-pilot-study
#9
Junya Sato, Megumi Mori, Satoru Nihei, Satoshi Takeuchi, Masahiro Kashiwaba, Kenzo Kudo
BACKGROUND: In an evaluation of chemotherapy-induced peripheral neuropathy (CIPN), objectivity may be poor because the evaluation is determined by the patient's subjective assessment. In such cases, management of neuropathy may be delayed and CIPN symptoms may become severe. In this pilot study, we attempted an objective evaluation of CIPN using a quantitative pain measurement system (Pain Vision(®)). METHODS: The subjects were patients with gynecologic cancer who underwent chemotherapy using taxane and platinum drugs...
2017: Journal of Pharmaceutical Health Care and Sciences
https://www.readbyqxmd.com/read/28747442/chemotherapy-induced-peripheral-neuropathy-clinical-trials-review-and-recommendations
#10
REVIEW
Jennifer S Gewandter, Roy Freeman, Rachel A Kitt, Guido Cavaletti, Lynn R Gauthier, Michael P McDermott, Nimish A Mohile, Supriya G Mohlie, A Gordon Smith, Mohamedtaki A Tejani, Dennis C Turk, Robert H Dworkin
OBJECTIVE: To assess the design characteristics and reporting quality of published randomized controlled trials (RCTs) for treatments of chemotherapy-induced peripheral neuropathy (CIPN) initiated before or during chemotherapy. METHODS: In this systematic review of RCTs of preventive or symptomatic pharmacologic treatments for CIPN initiated before or during chemotherapy treatment, articles were identified by updating the PubMed search utilized in the CIPN treatment guidelines published in the Journal of Clinical Oncology in 2014...
August 22, 2017: Neurology
https://www.readbyqxmd.com/read/28729624/taxanes-and-platinum-derivatives-impair-schwann-cells-via-distinct-mechanisms
#11
Satoshi Imai, Madoka Koyanagi, Ziauddin Azimi, Yui Nakazato, Mayuna Matsumoto, Takashi Ogihara, Atsushi Yonezawa, Tomohiro Omura, Shunsaku Nakagawa, Shuji Wakatsuki, Toshiyuki Araki, Shuji Kaneko, Takayuki Nakagawa, Kazuo Matsubara
Impairment of peripheral neurons by anti-cancer agents, including taxanes and platinum derivatives, has been considered to be a major cause of chemotherapy-induced peripheral neuropathy (CIPN), however, the precise underlying mechanisms are not fully understood. Here, we examined the direct effects of anti-cancer agents on Schwann cells. Exposure of primary cultured rat Schwann cells to paclitaxel (0.01 μM), cisplatin (1 μM), or oxaliplatin (3 μM) for 48 h induced cytotoxicity and reduced myelin basic protein expression at concentrations lower than those required to induce neurotoxicity in cultured rat dorsal root ganglion (DRG) neurons...
July 20, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28708674/chemotherapy-induced-peripheral-neuropathy-a-review-of-recent-findings
#12
Peggy Y Kim, Carrie E Johnson
PURPOSE OF REVIEW: Chemotherapy-induced peripheral neuropathy (CIPN) is a common, frequently chronic condition characterized by pain and decreased function. Given the growing number of cancer survivors and an increasing recognition of opioid therapy limitations, there is a need for critical analysis of the literature in directing an informed and thoughtful approach for the management of painful CIPN. RECENT FINDINGS: A PubMed search for 'chemotherapy-induced peripheral neuropathy AND pain' identifies 259 publications between 1 January 2016 and 31 March 2017...
October 2017: Current Opinion in Anaesthesiology
https://www.readbyqxmd.com/read/28702476/regulatable-transgene-expression-for-prevention-of-chemotherapy-induced-peripheral-neuropathy
#13
Daisuke Kawata, Zetang Wu
Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating complication associated with drug treatment of cancer for which there are no effective strategies of prevention or treatment. In this study, we examined the effect of intermittent expression of neurotophin-3 (NT-3) or interleukin-10 (IL-10) from replication-defective herpes simplex virus (HSV)-based regulatable vectors delivered by subcutaneous inoculation to the dorsal root ganglion (DRG) on the development of paclitaxel-induced peripheral neuropathy...
September 15, 2017: Molecular Therapy. Methods & Clinical Development
https://www.readbyqxmd.com/read/28699105/tapentadol-in-neuropathic-pain-cancer-patients-a-prospective-open-label-study
#14
Edvina Galiè, Veronica Villani, Irene Terrenato, Andrea Pace
Many chemotherapy treatments induce peripheral neuropathy (CIPN). These patients often experience neuropathic pain (NP) that reduces the quality of life. The aim of this prospective, open label study was to evaluate the efficacy and tolerability of tapentadol (TP) in patients affected by CIPN. CIPN were consecutively enrolled in a prospective open label study at the Neuro-Oncology Unit of the Regina Elena National Cancer Institute in Rome. During the titration phase, each patient initially received doses of TP 50 mg twice a day...
July 11, 2017: Neurological Sciences
https://www.readbyqxmd.com/read/28687964/predictors-of-the-usefulness-of-duloxetine-for-chemotherapy-induced-peripheral-neuropathy
#15
Yuko Kanbayashi, Megumi Inagaki, Hiroshi Ueno, Toyoshi Hosokawa
Duloxetine is an effective therapeutic agent for chemotherapy-induced peripheral neuropathy (CIPN). However, predictors of duloxetine response have not been adequately explored. Therefore, this retrospective study was performed to identify predictive factors of duloxetine response in CIPN patients to guide future strategies to improve the quality of life of patients undergoing chemotherapy. The participants were 74 cancer patients who were given duloxetine for relief of CIPN at our institute between October 2010 and January 2016...
August 2017: Medical Oncology
https://www.readbyqxmd.com/read/28674258/roles-of-transient-receptor-potential-ankyrin-1-in-oxaliplatin-induced-peripheral-neuropathy
#16
Takayuki Nakagawa, Shuji Kaneko
Chemotherapy-induced peripheral neuropathy (CIPN), characterized by symptoms of paresthesia, dysesthesia, numbness, and pain, is a common adverse effect of several chemotherapeutic agents, including platinum-based agents, taxanes, and vinca alkaloids. However, no effective prevention or treatment strategies exist for CIPN because the mechanisms underpinning this neuropathy are poorly understood. Recent accumulating evidence suggests that some transient receptor potential (TRP) channels functioning as nociceptors in primary sensory neurons are responsible for CIPN...
2017: Biological & Pharmaceutical Bulletin
https://www.readbyqxmd.com/read/28668762/mangafodipir-a-selective-cytoprotectant-with-special-reference-to-oxaliplatin-and-its-association-to-chemotherapy-induced-peripheral-neuropathy-cipn
#17
REVIEW
Jan Olof G Karlsson, Rolf Gg Andersson, Per Jynge
Oxaliplatin, in combination with 5-fluorouracil plus folinate (or capecitabine), has increased survival substantially in stage III colorectal cancer and prolonged life in stage IV patients, but its use is compromised because of severe toxicity. Chemotherapy-induced peripheral neuropathy (CIPN) is the most problematic dose-limiting toxicity of oxaliplatin. Oncologists included for years calcium and magnesium infusion as part of clinical practice for preventing CIPN. Results from a phase III prospective study published in 2014, however, overturned this practice...
August 2017: Translational Oncology
https://www.readbyqxmd.com/read/28664460/the-prevalence-and-pattern-of-chemotherapy-induced-peripheral-neuropathy-among-women-with-breast-cancer-receiving-care-in-a-large-community-oncology-practice
#18
Natalie B Simon, Michael A Danso, Thomas A Alberico, Ethan Basch, Antonia V Bennett
PURPOSE: To describe the prevalence, severity, and risk factors of chemotherapy-induced peripheral neuropathy (CIPN) and its impact on function and quality of life (QOL) among women treated for breast cancer in a large U.S. Community Oncology practice. METHODS: Women previously treated with taxane-based chemotherapy for early-stage breast cancer completed the EORTC QLQ-C30, QLQ-BR23, and QLQ-CIPN20. Subscales are scored 0-100; higher scores indicate greater symptom severity...
June 29, 2017: Quality of Life Research
https://www.readbyqxmd.com/read/28661695/treatment-of-chemotherapy-induced-peripheral-neuropathy-in-integrative-oncology-a-survey-of-acupuncture-and-oriental-medicine-practitioners
#19
Zhaoxue Lu, Jennifer Moody, Benjamin L Marx, Tracy Hammerstrom
OBJECTIVES: Complementary and alternative medicine is increasingly integrated into cancer care. We sought detail on the treatment of chemotherapy-induced peripheral neuropathy (CIPN) with acupuncture and oriental medicine (AOM) by surveying practitioners at integrative oncology (IO) sites across the United States. DESIGN: Online survey of licensed acupuncturists. SETTING/LOCATION: IO sites in the United States. SUBJECTS: Fifteen licensed acupuncturists who completed the survey between February 2014 and June 2014...
June 29, 2017: Journal of Alternative and Complementary Medicine: Research on Paradigm, Practice, and Policy
https://www.readbyqxmd.com/read/28649767/the-use-of-antioxidant-agents-for-chemotherapy-induced-peripheral-neuropathy-treatment-in-animal-models
#20
REVIEW
Larissa F Carvalho, Ana Maria F Silva, Adriana A Carvalho
Antineoplastic drugs such as cisplatin, oxaliplatin, paclitaxel and vincristin are widely used in the treatment of several solid and blood tumours. However, the severity of peripheral neuropathy caused by these agents can affect the patient's quality of life. The major symptoms of chemotherapy-induced peripheral neuropathy (CIPN) involve: sensory loss, paresthesia, dysesthaesia, numbness, tingling, temperature sensitivity, allodynia and hyperalgesia, in a "stocking and glove" distribution. Why many different chemotherapeutic agents result in similar neuropathy profiles is unclear...
October 2017: Clinical and Experimental Pharmacology & Physiology
keyword
keyword
115554
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"